Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05667948

Molecular Analysis and Treatment Options of Thymic Malignancies

Conditions: Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer

Sex: All
Ages: 18 Years – N/A
Enrollment: 500
Sponsor: Shanghai Chest Hospital

Location: China

Summary

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Eligibility Criteria

Inclusion Criteria:Histologically proven diagnosis of thymic malignancies18 years of age or olderAbility to understand and the willingness to sign a written informed consent document

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05667948). StuddyBuddy aggregates publicly available trial information.